Viatris Inc (VTRS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Viatris Inc stock (VTRS) is currently trading at $13.50. Viatris Inc PS ratio (Price-to-Sales) is 1.08. Analyst consensus price target for VTRS is $15.72. WallStSmart rates VTRS as Underperform.
- VTRS PE ratio analysis and historical PE chart
- VTRS PS ratio (Price-to-Sales) history and trend
- VTRS intrinsic value — DCF, Graham Number, EPV models
- VTRS stock price prediction 2025 2026 2027 2028 2029 2030
- VTRS fair value vs current price
- VTRS insider transactions and insider buying
- Is VTRS undervalued or overvalued?
- Viatris Inc financial analysis — revenue, earnings, cash flow
- VTRS Piotroski F-Score and Altman Z-Score
- VTRS analyst price target and Smart Rating
Viatris Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Viatris Inc (VTRS) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, peg ratio, price/sales. Concerns around return on equity and operating margin. Fundamentals are solid but monitor weak areas for improvement.
Viatris Inc (VTRS) Key Strengths (5)
Growing significantly faster than its price suggests
87.46% of shares held by major funds and institutions
Large-cap company with substantial market presence
Paying $1.08 for every $1 of annual revenue
Trading at 1.03x book value, attractively priced
Supporting Valuation Data
Viatris Inc (VTRS) Areas to Watch (5)
Company is destroying shareholder value
Earnings declining -70.60%, profits shrinking
Company is losing money with a negative profit margin
Very thin margins with limited operational efficiency
Modest revenue growth at 5.00%
Viatris Inc (VTRS) Detailed Analysis Report
Overall Assessment
This company scores 50/100 in our Smart Analysis, earning a C- grade. Out of 10 metrics analyzed, 5 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 1.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Institutional Own., Market Cap. Valuation metrics including PEG Ratio (0.14), Price/Sales (1.08), Price/Book (1.03) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, EPS Growth, Profit Margin. Growth concerns include Revenue Growth at 5.00%, EPS Growth at -70.60%, which may limit upside. Profitability pressure is visible in Return on Equity at -21.10%, Operating Margin at 7.78%, Profit Margin at -24.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -21.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 5.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (PEG Ratio, Institutional Own.) and negatives (Return on Equity, EPS Growth). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
VTRS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
VTRS's Price-to-Sales ratio of 1.08x trades at a 17% premium to its historical average of 0.92x (80th percentile). The current valuation is 20% below its historical high of 1.34x set in Dec 2020, and 74% above its historical low of 0.62x in Sep 2022. Over the past 12 months, the PS ratio has expanded from ~0.7x, reflecting growing market expectations outpacing revenue growth.
Compare VTRS with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Viatris Inc (VTRS) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Viatris Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 14.3B with 5% growth year-over-year. The company is currently unprofitable, posting a -24.6% profit margin.
Key Findings
Generating 551M in free cash flow and 816M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -24.6% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Dividend sustainability with a current yield of 3.6%. Watch payout ratio and free cash flow coverage.
Debt management: total debt of 14.7B is significantly higher than cash (975M). Monitor refinancing risk.
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Viatris Inc.
Bottom Line
Viatris Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(164 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 10:12:15 AM
About Viatris Inc(VTRS)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.